Allogene Therapeutics

$31.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.79 (-2.44%) Today

+$0.06 (+0.19%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ALLO and other stocks, options, and ETFs commission-free!

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA. The listed name for ALLO is Allogene Therapeutics, Inc. Common Stock.

CEO

David D. Chang

Employees

206

Headquarters

South San Francisco, California

Founded

2017

Market Cap

3.72B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.04M

High Today

$33.28

Low Today

$31.16

Open Price

$32.56

Volume

987.76K

52 Week High

$55.00

52 Week Low

$17.43

Collections

Analyst Ratings

76%

of 17 ratings

Buy

76%

Hold

24%

Sell

ALLO Earnings

-$0.68

-$0.45

-$0.23

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, Pre-Market